Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration
Authors:
- P RosenfeldPRP Rosenfeld
- S SchwartzSSS Schwartz
- M BlumenkranzMBM Blumenkranz
- J MillerJMJ Miller
- J HallerJHJ Haller
- J ReimannJRJ Reimann
- W GreeneWGW Greene
- N ShamsNSN Shams
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 112 (6) , 1048-1053.e4